• RotalactineTM is a 20 aa peptide identical to a fragment present in the Lactadherin of donkey milk (a traditional human food)
  • RotalactineTM prevents rotavirus infection by binding to the viral cellular receptors
  • In silico analysis predicts that RotalactineTM has no allergenic potential
  • RotalactineTM is stable in milk formulae and resistant to trypsin digestion
  • The aim is to eventually market RotalactineTM as a (novel) food ingredient/supplement of infant foods to reduce the incidence and the severity of rotavirus gastroenteritis
  • An alternative development path that considers RotalactineTM as a prescription therapy with documented clinical benefits is also possible and shares some of the initial steps with the food development path.